An International Phase Ib multicentre study to characterize the safety and tolerability of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with orally administered venetoclax, a selective Bcl-2 inhibitor, in patients with Acute Myeloid Leukaemia (AML).

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusActive
Effective start/end date23/10/1823/10/22